Is Alivus Life Sciences Limited a good investment? Alivus Life Sciences Limited (ALIVUS.BO) is currently trading at 1453.40 INR. Market analysts have a consensus price target of 1676.25 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 27.94. This valuation is generally in line with the broader market.
Earnings Schedule: Alivus Life Sciences Limited is expected to release its next earnings report on Jan. 28, 2027. The market consensus estimate for Forward EPS is 66.46.
For income investors, Alivus Life Sciences Limited pays a dividend yield of 0.34%. With a payout ratio of 9%, the dividend appears sustainable.
Yes, it pays an annual dividend of 5.00 INR (0.34% yield).
Alivus Life Sciences Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Jan. 28, 2027. The company currently has a trailing EPS of 54.43.
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited operates as a subsidiary of Nirma Limited.
| Year | Total Dividends |
|---|---|
| ▸2027 |
5.00 INR
|
| Sept. 13, 2027 (estimated) | 5.0000 |
| ▸2026 |
5.00 INR
|
| Sept. 11, 2026 | 5.0000 |
| ▸2025 |
5.00 INR
|
| Sept. 12, 2025 | 5.0000 |
| ▸2023 |
43.50 INR
|
| Nov. 8, 2023 | 22.5000 |
| March 29, 2023 | 21.0000 |
| ▸2022 |
10.50 INR
|
| Oct. 26, 2022 | 10.5000 |
| ▸2021 |
10.50 INR
|
| Dec. 10, 2021 | 10.5000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Alivus Life Sciences Limited | Sep 11, 2026 | Paid | 5.0 INR |
Community Discussion